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Department of Medicine I, Johannes Gutenberg University, Mainz, GermanyDespite great progress in diagnosis andmanagement of hepato- as well as Japan over the last 30–50 years [2]. Notably, confound-
cellular carcinoma (HCC), the exact biology of the tumor remains
poorly understood overall limiting the patients’ outcome. Detailed
analysis and characterization of the molecular mechanisms and
subsequently individual prediction of corresponding prognostic
traits would revolutionize both diagnosis and treatment of HCC
and is the key goal of modern personalized medicine. Over the
recent years systematic approaches for the analysis of whole
tumor genomes and transcriptomes as well as epigenomes
became affordable tools in translational research. This includes
simultaneous analyses of thousands of molecular targets using
microarray-based technologies as well as next-generation
sequencing. Although currently diagnosis and classiﬁcation of
hepatocellular cancers still rely on histological examination of
tumor sections, these technologies show great promise to advance
the current knowledge of hepatocarcinogenesis, complement
diagnostic classiﬁcation in a setting of microarray-aided pathol-
ogy, and rationalize the individual drug selection. This reviewaims
to summarize recent progress of system biological approaches in
hepatocarcinogenesis and outline potential areas for translational
application in a clinical setting. Further, we give an update about
known signaling pathways active inHCC, summarize the historical
application of whole genomic approaches in liver cancer and indi-
cate ongoing experimental research utilizing novel technologies in
diagnosis and treatment of this deadly disease. This will also
include the discussion and characterization of new molecular
and cellular targets such as Cancer Stem Cells (CSCs).
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) ranks among the most common
cancers worldwide and is the third leading cause of cancer death
overall accounting for more than half a million yearly deaths [1].
Although prevalence remains highest in Eastern Asia and Africa,
liver cancer incidence steadily increased in the Western worldJournal of Hepatology 20
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considerable inﬂuence on these numbers and presumably the
incidences in USA and Europe already peaked and stabilized in
the last years, reﬂecting the drop in hepatitis B infections and
improved treatment modalities against in chronic hepatitis C,
which constitutes the predominant risk factor in Western coun-
tries. Besides viral hepatitis, other chronic liver diseases due to
alcohol, nonalcoholic fatty liver disease (NAFLD), and other met-
abolic disorders are the main risk factors for the development of
HCC. Among these, metabolic syndrome and NAFLD is of particu-
lar interest in Western countries due to an alarming increase in
prevalence and high numbers of HCCs without underlying cirrho-
sis [3].
Currently, accurate diagnosis of frank HCC is achieved by
radiologic imaging techniques such as computer tomography
and magnetic resonance imaging. In inconclusive cases, the gold
standard still remains histology [4]. More difﬁcult is the proper
diagnosis of small HCC which frequently does not present with
typical vascular patterns in imaging tests and acquisition of reli-
able histological specimens often requires repetitive biopsies and
pathological interpretation is demanding. Therefore, one of the
most challenging aspects in hepatology is the detection of prema-
lignant lesions [5].
Curative therapeutic strategies for HCC involve surgical
resection, radio-frequency ablation and liver transplantation
[4]. Due to late detection and advanced underlying liver dis-
eases, these treatments are unavailable to the majority of the
patients [6].
HCC are highly resistant to conventional systemic therapies.
Although promising novel therapies and targets are currently
under evaluation (www.clinicaltrials.gov) the only systemic stan-
dard of care for patients with advanced HCC is sorafenib with a
mean survival beneﬁt of only 3 months [7–9].
Therefore, rationalizing and combining targeted therapies
according to genomic and epigenomic signatures of the corre-
sponding tumors will be a key goal in translational oncology
and might signiﬁcantly improve the treatment of liver cancer.
Over the last decade, a plethora of novel cutting edge technol-
ogies became available for cancer research. Microarray based-
approaches enabled the affordable and systematic analysis of
the whole cancer (epi-) genomes and transcriptomes. During
the last 10 years, detailed catalogs of somatic mutations in differ-
ent cancers were generated and accelerated the understanding of
carcinogenesis [10,11]. Moreover, the -omics revolution reﬁned12 vol. 56 j 267–275
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the common knowledge and improved translational research on
all levels of oncology, i.e. tumor classiﬁcation, biomarkers for
early detection, drug sensitivity, prediction of prognosis and,
most importantly, the development of novel therapeutic targets
[12–15].
Although the translation of systembiology into the actually
clinical routine is still in its infancy and currently pathological
examination of stained tissue sections or cytology remains the
main approach for diagnosis and classiﬁcation of tumors, the
molecular analysis of tumors and, in case of the liver, the dis-
rupted hepatic microenvironment [16] utilizing whole genome
and transcriptome approaches has great promise to complement
and advance the current knowledge in an adjunct setting of
microarray-aided pathology. This also includes novel ﬁelds of
systembiology including small RNAs and analysis of the epige-
nome [17].Signaling pathways and key oncogenic molecules
Despite the progress in surveillance and management of HCC, the
detailed molecular pathophysiology remains poorly understood
[18]. Hepatocarcinogenesis is believed to be a complex and
multi-step process involving the accumulation of both epigenetic
and genetic events. In particular, understanding of the sequence
of molecular events leading to progression from the chronically
diseased liver microenvironment to the occurrence of hyperplas-
tic and dysplastic nodules and ultimately to initiation and pro-
motion of cancer is still poorly understood [19]. Over the recent
years, extensive research focused on the identiﬁcation of key
oncogenes and tumor suppressors regulating cell cycle and apop-
tosis associated with the development of liver cancer. Addition-
ally, different signaling pathways known to be involved in
hepatocarcinogenesis have been studied intensively and are sub-
ject of many excellent reviews [18,20,21]. Among these, old dogs
such as p53, b-Catenin, ErbB family as well as new players like Igf
signaling and the Hippo pathway have been implicated in this
process. Widely accepted major pathways and molecules are
shown in Table 1.Table 1. Signaling in HCC.
Pathway/Signaling Process Ph
p53 Cell cycle, DNA damage, telomere stability Lo
dr
Af
Wnt/β-Catenin Target gene activation
(Myc, Cyclin D1, E-Cadherin, etc.)
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EGFR Proliferation, survival 
(via AKT, STATs, RAS/RAF)
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IGF Proliferation, development Pr
HGF/c-MET Proliferation, migration, morphogenesis M
TGF-B Development, differentiation, migration Ba
Nf-κB
VEGF Neo-angiogenesis Ag
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Genomics
The advances in affordable, high-throughput technologies made a
major contribution to the understanding of structural variation in
the human genome. Recent genome wide association studies
(GWAS) enrolling several thousand individuals led to the identi-
ﬁcation of liver disease speciﬁc susceptibility loci, including for
HCC [22–26]. Most of these studies employed high-throughput
microarray technology for SNP genotyping and array-based com-
parative genomic hybridization (aCGH). In contrast to disease
speciﬁc loci in well deﬁned patient collectives, the application
of whole genomic approaches for the analyses of the cancer gen-
ome yielded in enormous diversity and complexity underappreci-
ated by the traditional hypothesis-driven approaches mainly
focusing on few genes and/or pathways [10,11]. Cancer cell gen-
omes vary substantially from each other and even more dramat-
ically from those of normal and non-cancerous tissues [27]. In
contrast to tightly controlled genomes of normal tissue, the
mutational turn-over of cancer cells is rapid leading to dynamic
structural variations (CNV, LOH, aneuploidity) which needs to
be considered in translational cancer research.
Due to this complexity, the application of these approaches in
clinical routine currently remains limited. However, genomic
proﬁling has a great potential as diagnostic and prognostic tool
in personalized medicine.
Phenotypic and molecular heterogeneity is a hallmark of
hepatocellular cancers [28]. In particular, somatic alterations
and structural variation of genes important for cell cycle and
apoptosis are commonly associated with hepatocarcinogenesis
[20]. Other key molecular features frequently altered in liver
cancer involve the molecules and pathways listed in Table 1.
Array-based SNP genotyping and CGH approaches have been
extensively utilized to study structural abnormalities in both
liver cancer cell lines and primary tumors [20,21,29,30].
Recurrent copy number variations in various HCC cell lines
have already been demonstrated more than one decade agoenotypic features References
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[31,32]. Here, several genomic imbalances in HCC cell lines could
be associated with the pathogenesis of liver cancer thereby pro-
viding a basis for array-based molecular diagnosis and monitor-
ing of liver cancer. Recently, a similar approach was employed
using high-density single nucleotide polymorphism arrays and
uncovered 6 deletions and 126 ampliﬁcations shared by several
cell lines [33]. More detailed analyses of identiﬁed genes (FNDC3B
(3q26.3) and SLC29A2 (11q13.2)), previously not recognized in
the context of liver cancer, conﬁrmed consistent activation and
clinical correlation of these genes in several HCC datasets. More-
over, further evaluation demonstrated a functional role for cancer
cell proliferation and tumorigenicity, supporting the use of cell
lines for discovery of diagnostic and therapeutic biomarkers
and highlighting the power of whole genomic approaches. Since
the majority of HCCs develop over many years on the basis of
chronic inﬂammation, several redundant structural abnormalities
are associated with primary liver cancer involving chromosomal
regions with known driver genes in HCC such as c-MYC, RAS, and
p53 [21]. A comprehensive catalog of common aberrations from
both human and rodents is provided in the OncoDB.HCC
(http://oncodb.hcc.ibms.sinica.edu.tw) database [34]. This data-
base provides a useful, validated, and graphical integration of
published data derived from LOH analyses, aCGH, gene expres-
sion microarrays as well as proteomics which is publically assess-
able for validation of molecular targets. However, due to
molecular diversity of the alterations behind these loci, a major
obstacle remains the functional evaluation of individual genes
and identiﬁcation of driver genes.
Traditionally, the functional role of identiﬁed genes has been
studied using genetically modiﬁed mouse models [35,36].
Although these mouse models revealed important insights into
the molecular pathogenesis of liver cancer, they have several
shortcomings that limit their use for translational medicine [37].
Recently, a systematic strategy to identify potential driver
genes by integrating whole genome copy number data with gene
expression proﬁles of HCC patients was introduced [38]. By
selecting only genes with prognostic signiﬁcance in HCC patients,
a total of 50 putative driver genes were identiﬁed and function-
ally evaluated by RNAi. Further, by using the connectivity map
an association of the 50 genes with speciﬁc signaling molecules
in HCC could be established (mTOR, AMPK, and EGFR). The Con-
nectivity map is a publically available and powerful tool that
enables discovery of functional connections between drugs and
genes using a collection of genome-wide transcriptional expres-
sion data from cultured human cells treated with bioactive small
molecules [39,40].
In summary, over the recent decades extensive studies on
genomic changes revealed recurrent molecular changes associ-
ated with liver cancer. Availability of systematic and multidimen-
sional approaches for integrative genomic analyses of whole
genomes from both rodent and human tumors will further pro-
vide novel insights into molecular mechanisms in liver cancer,
that are likely to change the clinical management of this disease.
Transcriptomics
The use of gene-expression signatures is a powerful aid in the
development of novel diagnostic tools and for accurate and
unbiased identiﬁcation of prognostic subclasses and new cellular
targets in liver cancer [15,41,42]. Moreover, the use of whole
transcriptome data from patients before and after drug treatmentJournal of Hepatology 201to conduct pharmacogenomic analysis is a promising approach to
predict drug sensitivity and rationalize the use of drugs that
already has successfully been applied in several studies [14].
The era of whole transcriptomic analyses for HCC started almost
10 years ago [43–45]. Since then, more than 20 clinically relevant
gene expression signatures have been generated in HCC (Table 2).
The clinical utility of these studies is ranging from diagnosis over
prediction of survival and metastatic spread to prediction of
recurrent diseases.
The power of gene expression signatures to complement diag-
nostic strategies could be demonstrated in several studies. By uti-
lizing whole transcriptome analyses, a recent study tried to
discriminate and identify key regulatory molecules between cir-
rhotic (regenerative) nodules, dysplastic nodules (DN), and early
stage HCC [46]. As a result, the authors demonstrated that upreg-
ulation of MYC (8q) in dysplastic nodules could be used as a mar-
ker for malignant conversion. Notably, other markers commonly
associated to hepatocarcinogenesis (GPC3) could also be
detected.
Several hallmark prognostic signatures have been generated
for HCC by applying global gene expression analyses (Table 2).
Considerable heterogeneity across these signatures results in
different non-overlapping numbers of genes and differences in
prognostic relevance. Nevertheless, hallmark signaling of tumors,
well established for the majority of solid tumors, such as prolifer-
ative signaling, resistance against cell death, immortality,
pro-angiogenic signaling, activation of invasive and metastatic
programsaswell as pro-inﬂammatory signaling could also be reca-
pitulated for HCC [15,47,48]. Other pathways associated with bad
survival involved less studied pathways such as ubiquitination,
histone modiﬁcations as well as stemness traits [15,41,
49,50]. Since then, several of the identiﬁed markers have been
tested for their signiﬁcance as therapeutic targets and will be dis-
cussed later in this review [51–53]. Interestingly, a recent study
generated a prognostic signature from liver tissue adjacent to the
tumor, underlining the role of the diseased microenvironment
for the progression of liver cancer [16]. Villanueva et al. used an
integrative approach combining different published prognostic
gene expression proﬁling in HCC. As a result, they were able to
composite a prognostic model for HCC recurrence, based on gene
expression patterns in an independent set of tumor and adjacent
liver tissues conﬁrming the power of gene expression to comple-
ment ﬁndings from clinical and pathology analyses [54].
Several examples from different solid tumors exist on how
gene-expression proﬁles may be used in clinical practice for risk
prediction e.g. of recurrent disease (70-gene proﬁle (Mamma-
Print) [55], the 21-gene recurrence score (Oncotype DX) [56];
76-gene outcome Rotterdam signature [57]). In case of HCC,
besides the mentioned prognostic signatures several signatures
predictive for e.g. recurrence and metastasis have been generated
(Table 2). Already in 2002, a 12-gene signature was generated
that could predict early intrahepatic recurrence [43]. Later, a
group from NCI was able to generate a 17-gene immune
response-related signature from non-cancerous tissues in meta-
static livers that accurately predicted venous metastases, recur-
rence, and prognosis of HCC patients [58]. Although all of these
signatures had signiﬁcant predictive ability, the successful trans-
lation and rigorous evaluation for a clinical application is yet to
be generated.
Another useful application of gene expression data is the gen-
eration of publically available databases [59,60]. Although highly2 vol. 56 j 267–275 269
Table 2. Prognostic signatures in HCC.
Reference Clinical feature No. Genes Platform
Iizuka et al., 2003 [43] Recurrence 12 Affymetrix GeneChip 3.3
Ye et al., 2003 [45] Metastasis 153 Custom NCI array
Lee et al., 2004 [44] Survival 406 Custom NCI array
Budhu et al., 2006 [58] Metastasis 17 Custom NCI array
Kaposi-Novak et al., 2006 [121] Survival 111 Custom NCI array
Lee et al., 2006 [71] Survival 907 Custom NCI array
Wang et al., 2007 [135] Recurrence 57 Affymetrix HG-U133A+B
Boyault et al., 2007 [136] Proliferation 16 Affymetrix HG-U133A
Woo et al., 2008 [137] Survival 628 Affymetrix HG-U133A
Hoshida et al., 2008 [16] Recurrence 186 Illumina DASL
Coulouarn et al., 2008 [123] Survival 249 Custom NCI array
Yamashita et al., 2008 [42] Survival 59 Custom NCI array
Yoshioka et al., 2009 [138] Recurrence 172 AceGene Human oligo chip
Hoshida et al., 2009 [139] Proliferation 619 Multiple
Kapsoi-Novak et al., 2009 [46] Malignant transformation 85 Custom NCI array
Andersen et al., 2009 [101] Survival 276 Illumina humanRef-8
Woo et al., 2010 [50] Survival 625 Affymetrix HG-U133A
Roessler et al., 2010 [140] Metastasis, Recurrence 161 Affymetrix HG-U133A, Custom 
NCI array
Reviewuseful, successful integration of the obtained data in a disease
context, in particular for liver diseases, is usually missing.
We have recently tried to address the interaction of molecular
networks from gene expression data with their association to
human liver diseases and generated the ﬁrst comprehensive
and valid database for published molecular associations to close
the gap between genome wide microarray data and individual
highly validated data from PubMed [61]. Currently, Library of
Molecular Associations (LOMA) holds approximately 1260 manu-
ally conﬁrmed molecular associations for chronic liver diseases
such as HCC, CCC, liver ﬁbrosis, NASH/fatty liver disease, AIH,
PBC, and PSC. All data is available in a publicly available database
and can be accessed under: http://www.medicalgenomics.org/
databases/loma/news. A more global tool for cancer gene
expression and data-mining also including liver cancer data is
the Oncomine cancer database (https://www.oncomine.org/).
Selected genes across all analyses or for multiple genes in a
selected analysis can be simultaneously investigated and evalu-
ated for clinically important annotations [62].
Together, integration, systematic evaluation and data-min-
ing of different gene expression signatures as well as efﬁcient
application in a clinical setting (e.g., in microarray-aided
pathology) can be of indispensible value for modern personal-
ized medicine.
Epigenomics and micronomics
Growing evidence suggests that abnormal epigenetic regulation
is one of the fundamental mechanisms underlying many human
diseases including cancer [63]. Epigenetic alterations add fur-
ther complexity also to the pathogenesis of cancer. Changes in
DNA methylation are believed to be the early events in carcino-
genesis preceding allelic imbalances and lead to ultimately can-
cer progression [64]. Not surprisingly, epigenetic dysregulation,270 Journal of Hepatology 201in particular global hypomethylation and promoter hyperme-
thylation with subsequent silencing of tumor suppressor genes
has been increasingly recognized in the pathogenesis of liver
cancer [22]. As reported in other cancers, epigenetic changes
in the diseased liver microenvironment are supposed to be
early events also predisposing for liver cancer [65,66]. The con-
cept of a multistep, epigenetic driven hepatocarcinogenesis was
recently conﬁrmed in HBV-related liver cancers. A stepwise
increase of methylation in CpG islands of nine well described
genes was seen in a total of 133 samples (45 cirrhotic nodules,
29 LGDNs, 13 HGDNs, 14 eHCCs, and 32 progressed HCCs) [67].
Other studies could successfully use methylation patterns to
classify patients according to different etiological factors (e.g.,
HBV, HCV, alcohol) [68,69]. Furthermore, Calvisi et al. recently
revealed that changes in global and distinct methylation pat-
terns strongly correlate with the biological behavior of the
tumors and the clinical outcome of cancer patients [70]. Using
a 807 cancer-related gene panel in a group of 23 primary HCCs,
the same group could successfully separate primary HCC sam-
ples according to their subtype, again suggesting a correlation
between clinical outcome and methylation [49]. Consistent with
previous studies, patients with progenitor cell origin displayed
the worse clinical outcome [71].
Besides DNA methylation, other important epigenetic mecha-
nisms regulating gene expression are modiﬁcation of histones
(e.g., acetylation, methylation, phosphorylation, ubiquitylation,
and sumoylation) [72].
Although modiﬁcations of e.g. patterns of repressing histone
marks such as histone H3 lysine 27 and histone H3 lysine 9 as
well as activating histone H3 lysines 4 have signiﬁcant impact
on gene expression of critical genes associated with hepatocarci-
nogenesis, whole genomic approaches such as CHIP-CHIP and
CHIP-seq. are needed to address the role of these changes from
a more global perspective [29].2 vol. 56 j 267–275
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Furthermore, MicroRNAs are a class of epigenetically active
small regulatory RNAs that function to modulate protein expres-
sion [73]. This control allows for ﬁne-tuning of the cellular phe-
notype, including regulation of proliferation, cell signaling, and
apoptosis.
Aberrant expressions of MicroRNAs considerably contribute to
cancer initiation, propagation, and progression. Emerging evi-
dence indicates that certain MicroRNAs are frequently deregu-
lated in HCC, and that some speciﬁc MicroRNAs are associated
with the clinicopathological features of HCC [74]. These studies
demonstrated that MircoRNAs have essential roles in HCC pro-
gression by directly contributing to cell proliferation, apoptosis,
and metastasis of HCC and by targeting a large number of critical
protein-coding genes involved in hepatocarcinogenesis [75]. Not
surprising, that MicroRNAs are also associated with the regula-
tion of liver CSC [76–78].
In liver carcinogenesis, MicroRNAs have been found to have
both tumor suppressive (miR-122, miR-26, miR-223, Let-7 fam-
ily) and oncogenic activity (miR-221, miR-222, Mir-224, Mir-9,
and Mir-181). For some MicroRNAs (e.g., miR-221, miR-125B,
miR-26, miR-122) a prognostic relevance and prediction of drug
sensitivity (e.g., interferon) could be demonstrated [29,79–81].
In the last years, the power of MicroRNA proﬁling for classiﬁ-
cation of liver cancers has been demonstrated. MicroRNA proﬁles
revealed subclasses associated with histologic and etiologic fac-
tors, clinical phenotypes as well as mutations in several onco-
genic pathways such as b-Catenin and HNF1A [82]. Recently,
MicroRNA proﬁling of 89 HCC samples using a ligation-mediated
ampliﬁcation method revealed three distinct clusters of HCCs
reﬂecting the clinical behavior of the tumors. The functional role
of different identiﬁed MicroRNAs in particular of the miR-517
family was further investigated in cell lines and in an orthotopic
mouse model of liver cancer. As a result, the authors could asso-
ciate these MicroRNAs with increased proliferation, migration,
and invasion of HCC cells in vitro and in vivo, indicating the ther-
apeutic potential of MicroRNA based treatment modalities [83].
Novel technologies such as next generation sequencing will
likely contribute to a more detailed understanding of the role
of this interesting class of molecules in hepatocarcinogenesis
[84,85].Therapeutic translation and target therapeutics in HCC
Aberrant activation of different signaling pathways has been fre-
quently demonstrated in several solid tumors and raised substan-
tial interest for translational research also for liver cancer [86,87].
Highlighting the success of multi-tyrosinkinase inhibitor sorafe-
nib the major affected signaling pathways dysregulated in liver
cancer are involved in cellular functions, such as proliferation
(e.g., EGF, IGF, HGF, RAS/mitogen-activated protein kinase), apop-
tosis and survival (e.g., Akt, Nf-Kb), angiogenesis, etc. (e.g., VEGF,
PDGF) (Table 1) [7,9,20,47,88]. Gene expression analyses could
recapitulate most of these pathways and associate them with
molecular and prognostic subclasses [89,90].
The efﬁciency of whole genomic approaches for the identiﬁca-
tion of new molecular targets and the development of pathway-
orientated treatment strategies has been successfully applied in
different studies. Using an integrational approach of genomic
and transcriptomic as well as protein levels, Villaneuva et al.
could demonstrate the importance of mTOR signaling in the path-Journal of Hepatology 201ogenesis of liver cancer. Deregulation of the signaling was fre-
quently observed in primary human liver cancer specimens and
associated with different other relevant pathways (e.g., IGF and
EGF). Speciﬁc inhibitor and RNAi mediated blockade of the signal-
ing reduced the proliferation of cancer cells in vitro and in vivo,
indicating the potential for targeting the mTOR pathway in HCC
[91].
Other examples stem from a group at the NCI. The authors
made use of identiﬁed targets from prognostic gene expression
signatures for the treatment of HCC. Using whole genomic anal-
yses, the group previously identiﬁed COP1 and CSN5 as two crit-
ical regulators of p53 activity via proteasome-dependent
degradation in a screen for survival genes in human HCC
[15,46]. Subsequently, Lee et al. successfully demonstrated that
targeting of both genes can provide novel therapeutic modalities
against liver cancer cells in vitro. RNAi mediated silencing of each
gene, inhibited proliferation of HCC cells and increased apoptotic
cell death through the restoration of p53 function. The authors
further utilized a systemic delivery of the modiﬁed target siRNAs
by stable-nucleic-acid-lipid-particles (SNALP) and conﬁrmed
remarkable suppression of malignant growth and increased sur-
vival in an orthotopic xenograft mouse model without eliciting
overt immune response. Further, analysis of COP1 knockdown
signature revealed that the anti-tumor effect in vivo was driven
by p53-dependent apoptosis [51,52]. Together, these studies sug-
gest that systemic analyses of gene expression data can provide
an important new step towards potential clinical application in
personalized medicine.
Targeting of epigenetic modiﬁcations provides an exciting
new ﬁeld for therapeutic strategies in HCC. Epigenetic changes
are reversible by different therapeutic drugs leading to re-activa-
tion of silenced genes. Demethylating agents like 5-azacytidine as
well as HDAC inhibitors such as virinostat and valproic acid are
already approved for the treatment of hematologic cancers and
focus of many clinical studies in solid cancers (www.clinicaltri-
als.gov) [29].
Recently, the individual drug-response of HCC cell lines to the
DNA methylation inhibitor zebularine could be demonstrated
[49]. Using transcriptomic and epigenomic proﬁling, a drug
response signature could be generated that classiﬁed liver cancer
cells according to their corresponding sensitivity. In drug-sensi-
tive cell lines, epigenetic modulation caused cell cycle arrest
and increased apoptosis, whereas drug-resistant cell lines
showed up-regulation of dominant oncogenic networks (for
example, E2F1, MYC, and TNF). Therapeutic efﬁciency against
sensitive cancer cells was further revealed in vivo, leading to
increased survival and decreased pulmonary metastasis. Subse-
quent integration of the generated gene expression and demeth-
ylation response signatures allowed differentiation of patients
with HCC according to their clinical outcome. The study provided
ﬁrst insights into prediction of treatment success against epige-
netic chemotherapy and demonstrates the power of the phar-
maco-epigenomic approaches to identify cancer patients who
likely beneﬁt from targeting the cancer epigenome.Novel cellular targets in HCC: a role for hepatic Cancer Stem
Cells
The hierarchic model of cancer origin is based on the assumption
that tumor heterogeneity originates from a small population of so2 vol. 56 j 267–275 271
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called Cancer Stem Cell (CSC) that share multiple characteristics
of tissue stem cells [92]. This model does not contradict the clas-
sical stochastic tumor model, it just redeﬁnes the importance of
cells with aberrant differentiation capacity and is helpful to
approach the above mentioned tumor heterogeneity. Moreover,
while the cellular origin remains undeﬁned in the term CSC, the
existence of these cells is of fundamental importance for transla-
tional cancer research and harbors broad clinical implications, in
particular from the therapeutic point of view [92,93].
Many studies tried to elucidate the presence of CSC in hepato-
carcinogenesis and mainly employed immunogeneic as well as
functional isolation methods for prospective isolation [79,94].
Few studies also addressed the clinical relevance of CSC for treat-
ment and outcome of patients. Drug resistance with subsequent
initiation of relapses and/or metastatic spread of tumor cells
are supposed to be fundamental properties of CSCs, [95] thereby
making CSC a prime cellular target for diagnostic and therapeutic
strategies in multi-resistant cancers such as HCC, which are char-
acterized by poor therapeutic response and fatal outcome of the
patients [88,96]. Speciﬁc targeting liver CSCs in pre-clinical stud-
ies, e.g. by targeting EpCAM + cells by RNAi mediated inhibition
or forced differentiation using oncostatin M in combination with
conventional chemotherapy, showed increased apoptosis and
decreased cell proliferation, indicating the potential of CSCs for
therapeutic modalities in liver cancer [97,98]. Recently, CD13
was identiﬁed as a new marker of hepatic CSCs by using gene
expression proﬁling of isolated Side-Population cells from liver
cancer cell lines [99,100]. The authors found that CD13 enriches
for semiquiescent CSCs and showed that targeting these cells
might provide a way to treat HCC. Direct targeting of this mole-
cule by a CD13 inhibitor in combination with ﬂuorouracil (5-
FU) drastically reduced tumorigenicity and self-renewing capac-
ity of the cells.
Although the existence of these CSC in liver cancer is still mat-
ter of controversies, several studies demonstrated the clinical sig-
niﬁcance of stem-like gene expression signatures for liver cancer
patients. The notion that HCC patients who share gene features of
progenitor cells have a worse clinical outcome has been repeat-
edly demonstrated.
Andersen et al. recently established CK19 as a relevant marker
of neoplastic transformation in a rat model of liver cancer. Like-
wise, a CK19 gene expression signature enriched for ‘stemness’,
successfully classiﬁed HCC patients according to the clinical out-
come [54,101].
In human, the concept of CK19 as a clinical surrogate of a pro-
genitor cell origin could further be conﬁrmed. CK19 positive
tumors highly overlapped with the proliferation subclass gener-
ated by earlier studies of the authors. A human-based CK19 gene
expression signature was highly associated with the CK19 rat sig-
nature and other progenitor-derived signatures [54].Future perspectives
Over the last decades considerable advancements in the clinical
management of liver cancer have been made. Due to efﬁcient sur-
veillance, improved diagnostic assessment, as well as increasing
efforts in therapeutic strategies, liver cancer emerged from a uni-
versally deadly to a treatable disease [4]. Although whole geno-
mic approaches evolved to affordable tools in cancer research
with a dramatic impact on translational science, there remains272 Journal of Hepatology 201a signiﬁcant gap for the translational applications of these tech-
nologies in liver cancer.
The exact molecular mechanisms of how currently used tar-
geted therapies (e.g., sorafenib, erlotinib) contribute their efﬁcacy
in HCC are still unknown and molecular classiﬁcation of HCC
patients into relevant subclasses based on individual (epi-)geno-
mic tumor signatures as well as individualized therapeutic
approaches remain a futuristic vision. Successful translation into
clinical practice will require prospective application of high-
throughput whole genomic approaches and standardized valida-
tion in independent patient cohorts. Further, pharmaco-genomic
analyses should accompany clinical trials to rationalize the com-
bination of available targeted therapies and unravel the mecha-
nisms of drug resistance.
Next-generation technologies such as deep sequencing are
promising tools to further increase our understanding of cancer
biology and extensive application of these novel high-throughput
technologies such as already performed in the International Can-
cer Genome Consortium (http://www.icgc.org) and the Cancer
Genome Atlas (http://cancergenome.nih.gov) will undoubtfully
contribute to the identiﬁcation of new molecular targets. Several
recent studies already successfully employed deep sequencing
approaches and showed stepwise progression of genomic varia-
tions during cancer progression in different cancers, whereby
concomitantly identifying novel mutations, e.g., during the acqui-
sition of metastatic traits, that could be used for drug develop-
ment [102,103]. Large-scale and systematic application of novel
technologies on all molecular levels i.e. genome, transcriptome,
proteome, and epigenome are urgently needed to decode the
biology of hepatocellular cancers and improve the limited prog-
nosis of our patients. One of the major challenges of this century
will be the meaningful interpretation and application of the enor-
mous ﬂood of data in a meaningful clinical context. Further, inte-
gration of this vast amount of data and assembly of cumulative
hypotheses will be extremely challenging in translational science.
Another major obstacle is the integration of different biological
layers (genome, transcriptome, proteome, epigenome), in partic-
ular due to a lack of sufﬁcient bioinformatics strategies. Further
increasing the biological complexity, biological/pathological
changes observed in individual biological compartments do not
necessarily have to be conforming to each other. It has been well
established in model organisms that in normal liver tissue,
approximately 25% of changes in gene expression are not accom-
panied by simultaneous changes in protein abundance. This is a
particular problem for low expressed genes [104]. However, it
has also been established that ﬁndings of differential gene and
protein expression may complement one another and thus lead
to a more comprehensive view of biological changes. First,
approaches to generate algorithms and platforms for integrating
all these diverse biological information have been made, e.g.,
BiologicalNetworks2.0 [105]. However, the currently available
platforms artiﬁcially reduce the information to one biological
level, i.e. integrating all data according to the transcriptome
and changes in protein expression are treated as additional tran-
scriptomic changes. Although those platforms are a promising
step ahead, they are far from offering a comprehensive data
integration.
However, unraveling the tight and complex interactions
between the diverse biological levels and dissecting the different
signaling pathways activated during hepatocarcinogenesis will
certainly lead to a whole new perception of HCC development2 vol. 56 j 267–275
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and subsequently disclose novel strategies for the diagnosis and
treatment of HCC. This also requires the consequent, systematic
and standardized collection of tissue specimens from HCC
patients (e.g., biopsies) for subsequent prospective molecular
analyses, to condense the unprecedented new insights into tumor
biology that originate from high-throughput technologies into
clinically relevant information. Therefore, tight integration of
expertise and knowledge from clinicians, biologists, and bio-
informaticians will be essential to achieve this ambitious goal.
The next years will demonstrate if hepatology can take the chal-
lenges of modern molecular medicine.Conﬂict of interest
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